Immune system modulation in the highly sensitized transplant candidate.
D000208:Acute Disease; D000328:Adult; D002311:Cardiomyopathy, Dilated / Q000150:complications; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D006333:Heart Failure / Q000209:etiology / Q000601:surgery; D016027:Heart Transplantation / Q000009:adverse effects* / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008403:Mass Screening; D018579:Patient Selection; D010956:Plasmapheresis; D011300:Preoperative Care / Q000379:methods*; D012307:Risk Factors; D014181:Transplantation Immunology
D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide